AstraZeneca (AZN) admits 14,120 new employee scheme shares to LSE

Rhea-AI Filing Summary

AstraZeneca PLC reported the admission of 14,120 additional ordinary shares of $0.25 each to trading on the Main Market of the London Stock Exchange. These shares were issued between 1 May 2026 and 31 May 2026 under the company’s employee share schemes and an existing block admission dated 29 January 2021.

Following this admission, the total number of AstraZeneca ordinary shares in issue is 1,551,009,750, which are fully fungible with the existing ordinary shares.

Key Figures

New shares admitted: 14,120 shares Total shares in issue: 1,551,009,750 shares Par value per share: $0.25 per share +2 more

5 metrics

New shares admitted 14,120 shares Issued between 1 May 2026 and 31 May 2026

Total shares in issue 1,551,009,750 shares After admission of further securities

Par value per share $0.25 per share Ordinary shares of AstraZeneca PLC

Admission period 1 May 2026–31 May 2026 Period when new shares were issued

Block admission date 29 January 2021 Existing block admission covering these shares

Key Terms

block admission, employee share schemes, Public Offers and Admissions to Trading Regulations 2024, fungible, +1 more

5 terms

block admission regulatory

"admitted under a block admission dated 29 January 2021"

employee share schemes financial

"Admission of shares under the Company's employee share schemes"

Public Offers and Admissions to Trading Regulations 2024 regulatory

"in accordance with The Public Offers and Admissions to Trading Regulations 2024"

A set of regulatory rules titled “public offers and admissions to trading regulations 2024” governs how companies can sell securities to the public and how those securities can be listed or admitted for trading on organized markets. These rules ensure companies disclose clear information, follow standardized steps and meet eligibility checks so investors can compare opportunities, understand risks, and trade with confidence—like a traffic code that keeps markets orderly and safer for everyone.

fungible financial

"Fungibility | Fully fungible with existing Ordinary Shares"

Fungible describes an asset that is interchangeable with another of the same kind because each unit holds the same value and function. For investors this matters because fungible assets are easier to trade, price, and store—think of cash or grains where one unit can replace another, unlike a unique artwork or a signed collectible which may be worth more or less depending on provenance. Fungibility affects liquidity, market efficiency, and how assets are settled or regulated.

Main Market of the London Stock Exchange market

"admitted to trading on the Main Market of the London Stock Exchange"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of June 2026

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Admission of Further Securities to Trading

1 June 2026

Notification of Admission of Further Securities to Trading (PRM 1.6.4R)

The following notification is made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R.

1	Details of the issuer
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
2	Details of the transferable securities admitted to trading
a)	Name, type and identification code	Ordinary Shares of $0.25 each ISIN: GB0009895292
b)	Regulated market	London Stock Exchange - Main Market
c)	Number of further securities issued and admitted	14,120
d)	Total number of securities in issue following admission	1,551,009,750
e)	Fungibility	Fully fungible with existing Ordinary Shares
3	Admission details
a)	Date of admission	Issued between 1 May 2026 to 31 May 2026 (admitted under a block admission dated 29 January 2021)
b)	Prospectus information	Prospectus: N/A Supplementary: N/A Company's webpage: https://www.astrazeneca.com
c)	Coverage of notification	Admission of shares under the Company's employee share schemes from 1 May 2026 up to 31 May 2026, admitted to trading on the Main Market of the London Stock Exchange under the Company's existing block admission of shares dated 29 January 2021.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 01 June 2026

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary

FAQ

What did AstraZeneca PLC (AZN) report in this June 2026 Form 6-K?

AstraZeneca reported the admission of 14,120 additional ordinary shares to trading on the London Stock Exchange, issued under its employee share schemes between 1 May 2026 and 31 May 2026.

How many AstraZeneca (AZN) shares are in issue after the new admission?

After admitting the new shares, AstraZeneca has a total of 1,551,009,750 ordinary shares in issue, all fully fungible with the existing ordinary shares already trading on the London Stock Exchange.

What is the source of the additional AstraZeneca (AZN) shares admitted to trading?

The additional 14,120 AstraZeneca ordinary shares were issued under the company’s employee share schemes and admitted pursuant to an existing block admission dated 29 January 2021 on the London Stock Exchange.

On which market are the new AstraZeneca (AZN) shares admitted to trading?

The 14,120 additional AstraZeneca ordinary shares are admitted to trading on the Main Market of the London Stock Exchange, alongside the company’s existing fully fungible ordinary shares.

Do the newly admitted AstraZeneca (AZN) shares differ from existing ordinary shares?

The newly admitted 14,120 AstraZeneca ordinary shares are described as fully fungible with existing ordinary shares, meaning they have the same rights and characteristics as shares already in issue.